OnKure Therapeutics, Inc.
OKURHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, OnKure Therapeutics, Inc. (OKUR) is listed under Biotechnology. Valued at $101.8M, OKUR is a micro-cap name in its sector. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.
Market Cap
$101.8M
Beta
0.75
P/E (TTM)
—
P/E (Fwd)
-1.65
EPS (TTM)
$-2.99
EPS (Fwd)
$-1.53
ROE
-46.9%
ROA
-29.3%
Cash
$176.4M
Total Debt
$926,000
Free CF
-$27.1M
52W Change
-24.1%
Annual Financials
Cash vs Debt
Where OKUR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, OKUR finished 42.16% below its 150-day moving average ($3.89) and 38.02% below its 200-day moving average ($3.63). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OKUR overbought or oversold?
At the October 20, 2026 close, OKUR's RSI(14) was 36.7, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
OnKure Therapeutics, Inc. holds $176.4M in cash against $926K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$27.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -46.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, OKUR has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence OnKure Therapeutics, Inc.'s trajectory.